Frog-Derived Peptide Shows Promise as Sepsis Treatment in Mice | Research

The takeaway

Cathelicidin-MH, a novel antimicrobial peptide from frog skin, protected mice from lethal sepsis by combining antimicrobial activity, LPS neutralization, and coagulation suppression.

Multi-mechanism sepsis protection
Combines antimicrobial killing, LPS neutralization, coagulation suppression, and MAPK signaling inhibition

What the researchers found

Cathelicidin-MH protected mice from lethal sepsis through a unique combination of antimicrobial activity, LPS neutralization, coagulation suppression (affecting tPA, plasmin, tryptase, elastase, thrombin, and chymase), and MAPK signaling inhibition.

Why it matters

Sepsis kills more than 11 million people annually and current treatments are limited. A peptide that simultaneously fights infection, neutralizes endotoxin, and controls coagulation addresses multiple sepsis mechanisms at once.

The numbers in context

Active vs Gram-negatives and fungi; 6 coagulation enzymes inhibited; 2 sepsis models; reduced cytokines; blocked MAPK

How the study worked

Peptide isolation and structural characterization. In vitro antimicrobial and coagulation assays. In vivo LPS-induced and cecal ligation/puncture sepsis models in mice. Organ pathology, inflammatory cytokine, and signaling pathway analysis.

Who was studied

Mice with LPS-induced and cecal ligation/puncture sepsis

What this study cannot tell us

Mouse sepsis models don't perfectly predict human sepsis outcomes. Peptide stability, pharmacokinetics, and manufacturing costs not addressed. Published in eLife (high-quality journal) but still preclinical.

How to read the evidence

Published in eLife with comprehensive in vitro and in vivo validation including two sepsis models. High-quality preclinical evidence.

When this study was published

Published in 2021, representing cutting-edge antimicrobial peptide research from amphibian sources.

The bigger picture

Most antimicrobial peptides are studied for their direct killing activity, but cath-MH's additional coagulation-suppressing and anti-inflammatory properties make it especially suited for sepsis, where uncontrolled coagulation and inflammation are major drivers of organ failure and death.

Questions still open

Can cath-MH be produced at scale for clinical use?
Would the coagulation-suppressing effects increase bleeding risk at therapeutic doses?
How does cath-MH compare to other anti-sepsis peptide candidates?

Common questions

Why is a frog skin peptide useful for treating sepsis?

Frogs produce antimicrobial peptides in their skin as part of their immune defense. Cathelicidin-MH from the Microhyla frog is unique because it doesn't just kill bacteria — it also neutralizes bacterial toxins, controls blood clotting, and reduces inflammation, addressing multiple aspects of sepsis simultaneously.

How is this different from antibiotics for sepsis?

Antibiotics kill bacteria but don't address the other deadly aspects of sepsis — the toxin release, uncontrolled clotting, and inflammatory organ damage. Cath-MH tackles all of these at once, which could make it more effective as a sepsis therapeutic.

Read the original research

Characterization and functional analysis of cathelicidin-MH, a novel frog-derived peptide with anti-septicemic properties.

eLife, 10

View on PubMed ↗Publisher’s paper ↗

Citation

Chai, Jinwei; Chen, Xin; Ye, Tiaofei; Zeng, Baishuang; Zeng, Qingye; Wu, Jiena; Kascakova, Barbora; Martins, Larissa Almeida; Prudnikova, Tatyana; Smatanova, Ivana Kuta; Kotsyfakis, Michail; Xu, Xueqing. (2021). Characterization and functional analysis of cathelicidin-MH, a novel frog-derived peptide with anti-septicemic properties.. eLife, 10. https://doi.org/10.7554/eLife.64411